Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression

Cancer Research

Volumn 67, Issue 2, 2007, Pages 563-572

  Liao, Debbie ^a,b   Corle, Courtney ^a   Seagroves, Tiffany N ^a,c   Johnson, Randall S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; BREAST HYPERPLASIA; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENETIC TRANSCRIPTION; IN VITRO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION;

ANIMALS; CELL GROWTH PROCESSES; DISEASE PROGRESSION; FEMALE; HYPERPLASIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; MALE; MAMMARY NEOPLASMS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM METASTASIS; TRANSCRIPTION, GENETIC;

EID: 33846652552     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2701     Document Type: Article

References (37)

1. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68-72.
2. 2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
3. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 2004;19:176-82.
4. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
5. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
6. Bos R, van der Groep P, Greijer AE, et al. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003;97:1573-81.
7. Vleugel MM, Greijer AE, Shvarts A, et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer. J Clin Pathol 2005;58:172-7.
8. Gruber G, Greiner RH, Hlushchuk R, et al. Hypoxia-inducible factor 1α in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res 2004;6:R191-8.
9. Dales JP, Garcia S, Meunier-Carpentier S, et al. Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005;116:734-9.
10. Kronblad A, Jirstrom K, Ryden L, Nordenskjold B, Landberg G. Hypoxia inducible factor-1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer 2006;118:2609-16.
11. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 2001;93:309-14.
12. Lin EY, Jones JG, Li P, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003;163:2113-26.
13. Seagroves TN, Hadsell D, McManaman J, et al. HIF1α is a critical regulator of secretory differentiation and activation, but not vascular expansion, in the mouse mammary gland. Development 2003;130:1713-24.
14. Wagner KU, McAllister K, Ward T, et al. Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 2001;10:545-53.
15. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 2003;112:645-57.
16. Blouw B, Song H, Tihan T, et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003;4:133-46.
17. Grunstein J, Roberts WG, Mathieu-Costello O, Hanaban D, Johnson RS. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999;59:1592-8.
18. Medina D, Kittrell F. Establishment of mouse mammary cell lines. In: Ip MM, Asch BB, editors. Methods in mammary gland biology and breast cancer research. New York: Plenum Publishers; 2000. p. 137-45.
19. Ryan HE, Lo J, Johnson RS. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17:3005-15.
20. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7.
21. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69 Suppl 3:4-10.
22. Seagroves TN, Ryan HE, Lu H, et al. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 2001;21:3436-44.
23. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006;3:187-97.
24. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001;276:9519-25.
25. Goda N, Ryan HE, Khadivi B, et al. Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003;23:359-69.
26. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
27. North S, Moenner M, Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett 2005;218:1-14.
28. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654-62.
29. Sung Soo Rang YKC, Min Hee Hur, et al. Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res 2002;93:1123-8.
30. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
31. Graham CH, Forsdike J, Fitzgerald CJ, Macdonald-Goodfellow S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 1999;80:617-23.
32. Munoz-Najar UM, Neurath KM, Vumbaca F, Claffey KP. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 2005;25:2379-92.
33. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003;63:1138-43.
34. Lester RD, Jo M, Campana WM, Gonias SL. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem 2005;280:39273-7.
35. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-80.
36. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006;440:1222-6.
37. Woelfle U, Cloos J, Sauter G, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 2003;63:5679-84.